<unk> (recombinant) is a blood coagulation<unk>  VIII<unk>  VIII) that is FDA approved for the treatment of * Hemophilia A for:
On-demand treatment and control of bleeding episodes.
Perioperative management of bleeding.
Routine prophylaxis to reduce the frequency of bleeding episodes..   Common adverse reactions include paresthesia, headache, injection site inflammation, injection site pain, non-neutralizing anti-Factor VIII antibody formation, back pain, vertigo, and dry mouth..
On-demand treatment and control of bleeding episodes.
Perioperative management of bleeding.
Routine prophylaxis to reduce the frequency of bleeding episodes..   Common adverse reactions include paresthesia, headache, injection site inflammation, injection site pain, non-neutralizing anti-Factor VIII antibody formation, back pain, vertigo, and dry mouth..
Antihemophilic factor 
Antihemophilic Factor 
Lupus anticoagulant
Immunoglobulin E
Factor ix complex
Fibrinolysin
Thrombus precursor protein 
Antithrombin III